Range Cancer Therapeutics ETF Rating → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free CNCR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share RatingsStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrendsStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends Range Cancer Therapeutics ETF Aggregate Rating and Price Target (2024)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CNCR Aggregate RatingModerate Buy2.72Holdings in CNCR have an aggregate rating of Moderate Buy based on 352 analyst ratings issued in the past year covering 50 companies (74.8% of the portfolio).CNCR Aggregate Price Target$30.04107.16% UpsideHigh Prediction$41.61Average Prediction$30.04Low Prediction$20.71Holdings in CNCR have an aggregate price target of $30.04 and a range of $20.71 to $41.61 covering 50 companies (74.8% of the portfolio).CNCR Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy16 Buy rating(s)Moderate Buy26 Moderate Buy rating(s)Hold7 Hold rating(s)Reduce1 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Range Cancer Therapeutics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 50 CNCR Holdings Export to ExcelWeightIn ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.74%ELVNEnliven Therapeutics$22.57+0.1%2 of 5 stars3.00$34.00 50.6%1Insider SellingShort Interest ↑News Coverage2.74%GERNGeron$3.55+2.3%4 of 5 stars2.80$6.10 71.8%5Positive News2.25%ITOSiTeos Therapeutics$16.74-2.4%2 of 5 stars3.00$31.00 85.2%3Positive News2.20%DCPHDeciphera Pharmaceuticals$25.54+0.0%3 of 5 stars2.30$24.17 -5.4%10Short Interest ↓Positive News2.20%ACRVAcrivon Therapeutics$7.72+2.0%3 of 5 stars2.86$22.57 192.4%7Positive News1.93%NUVBNuvation Bio$3.10+3.7%3 of 5 stars3.00$6.60 112.9%5News CoverageHigh Trading Volume1.87%IBRXImmunityBio$6.42-2.9%0 of 5 stars2.00$6.00 -6.5%1Positive News1.84%CGEMCullinan Therapeutics$23.50+3.1%2 of 5 stars3.00$32.00 36.2%7Short Interest ↑Gap Down1.71%ERASErasca$2.52+1.6%2 of 5 stars2.80$6.83 171.2%5Analyst Forecast1.68%LYELLyell Immunopharma$2.77+4.1%1 of 5 stars2.50$5.50 98.6%21.64%RVMDRevolution Medicines$38.33+0.4%4 of 5 stars3.10$43.20 12.7%10Positive News1.61%IPHAInnate Pharma$2.74-0.4%2 of 5 stars3.00$9.75 255.8%1Short Interest ↓High Trading Volume1.60%BPMCBlueprint Medicines$105.56-0.8%1 of 5 stars2.53$103.94 -1.5%17Positive News1.57%JANXJanux Therapeutics$53.50+6.1%3 of 5 stars2.88$66.29 23.9%8Analyst Forecast1.53%HCMHUTCHMED$18.53-1.7%2 of 5 stars2.75$29.70 60.3%4Short Interest ↑Positive News1.53%TSVT2seventy bio$4.23-3.0%3 of 5 stars2.60$12.86 204.0%10Positive News1.50%MRKMerck & Co., Inc.$125.54+0.8%4 of 5 stars2.58$131.33 4.6%12Dividend AnnouncementHigh Trading Volume1.48%XNCRXencor$23.76-0.5%4 of 5 stars2.86$35.43 49.1%7Positive News1.48%NRIXNurix Therapeutics$15.75+1.1%2 of 5 stars2.88$21.88 38.9%8Gap UpHigh Trading Volume1.47%BNTXBioNTech$100.60+1.9%2 of 5 stars2.20$111.70 11.0%10Analyst ForecastShort Interest ↓1.42%REGNRegeneron Pharmaceuticals$980.16+1.1%4 of 5 stars2.76$989.36 0.9%21Insider SellingHigh Trading Volume1.41%AGENAgenus$15.69+3.8%4 of 5 stars3.00$70.00 346.1%3Gap Down1.41%BCYCBicycle Therapeutics$22.19+1.2%2 of 5 stars2.86$46.86 111.2%71.40%STROSutro Biopharma$4.23-2.5%5 of 5 stars3.00$12.50 195.9%8Positive News1.40%MORMorphoSys$18.39+0.2%0 of 5 stars2.29$11.78 -35.9%7Short Interest ↑1.36%MRUSMerus$53.24-7.1%2 of 5 stars3.00$63.80 19.8%12Analyst ForecastAnalyst Revision1.36%FHTXFoghorn Therapeutics$5.83+0.5%1 of 5 stars2.67$14.50 148.7%3Positive NewsHigh Trading Volume1.35%AURAAura Biosciences$7.352 of 5 stars3.00$21.00 185.7%3News CoveragePositive News1.35%IGMSIGM Biosciences$8.33-4.4%4 of 5 stars2.50$17.89 114.8%8Short Interest ↓1.34%KURAKura Oncology$20.61-0.4%3 of 5 stars2.86$27.94 35.6%7Positive News1.34%DAWNDay One Biopharmaceuticals$13.27-2.4%3 of 5 stars2.86$37.67 183.8%7Short Interest ↓Analyst Revision1.34%INBXInhibrx$16.25+2.5%5 of 5 stars2.00$27.00 66.2%2Upcoming EarningsInsider SellingShort Interest ↓News Coverage1.33%GMABGenmab A/S$28.20+0.8%3 of 5 stars2.38$48.50 72.0%13Short Interest ↑1.32%TYRATyra Biosciences$16.22+3.0%2 of 5 stars2.75$23.50 44.9%4Short Interest ↓Positive News1.29%PGENPrecigen$1.40+5.3%4 of 5 stars2.60$9.00 542.9%5Positive News1.25%SMMTSummit Therapeutics$8.69-20.4%1 of 5 stars3.00$10.50 20.9%2Analyst ForecastOptions VolumeNews CoverageGap DownHigh Trading Volume1.24%EXELExelixis$21.69+4.4%5 of 5 stars2.59$26.13 20.4%17Insider BuyingPositive NewsGap Up1.24%PRLDPrelude Therapeutics$3.85-0.5%2 of 5 stars1.67$5.25 36.4%3Positive NewsHigh Trading Volume1.22%SNDXSyndax Pharmaceuticals$19.27-0.1%4 of 5 stars2.91$34.42 78.6%11Positive News1.22%RCUSArcus Biosciences$15.07+0.9%2 of 5 stars2.88$41.25 173.7%8News Coverage1.20%VORVor Biopharma$1.35+0.7%3 of 5 stars3.00$12.50 825.9%5Positive News1.19%SWTXSpringWorks Therapeutics$41.46-2.7%1 of 5 stars3.00$68.83 66.0%6Analyst Forecast1.19%KYMRKymera Therapeutics$32.11-0.2%1 of 5 stars2.50$42.70 33.0%121.18%IDYAIDEAYA Biosciences$36.55+2.1%3 of 5 stars3.00$46.80 28.0%12Insider SellingNews CoverageGap Down1.17%RLAYRelay Therapeutics$6.41+1.7%2 of 5 stars3.00$22.20 246.3%7News Coverage1.16%SDGRSchrödinger$21.52-1.2%2 of 5 stars2.67$42.80 98.9%9News CoveragePositive NewsGap Down1.15%RXRXRecursion Pharmaceuticals$8.28-6.7%2 of 5 stars2.50$14.33 73.1%4Insider Selling1.14%YMABY-mAbs Therapeutics$12.10+0.7%2 of 5 stars2.33$17.33 43.3%6Insider SellingShort Interest ↑News CoverageHigh Trading Volume1.12%KPTIKaryopharm Therapeutics$0.97+2.1%4 of 5 stars2.60$4.80 395.3%51.12%IMTXImmatics$11.03-2.2%1 of 5 stars3.00$16.00 45.1%2 This page (NASDAQ:CNCR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
